South Texas Accelerated Research Therapeutics (START)-Midwest

Grand Rapids, Michigan 49546

7 studies enrolling now · 19 studies all time

What they study most

Acquired Resistance to KRAS G12C Inhibitor, Advanced Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, All Malignancies, BRAF, BRAF Gene Mutation, BRAF Mutation-Related Tumors, BRAF V600 Mutation, BRAF V600E, Brain Metastases, CCNE1 Amplified Advanced Solid Tumors

Studies at this site

• Study of AUBE00 in Patients With Solid Tumors — Recruiting now
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — Recruiting now
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — Recruiting now
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) — Recruiting now
• A Study of MGC028 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors — Stopped early
• Study of Oral MRT-2359 in Selected Cancer Patients — Running, not enrolling
• A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). — Stopped early
• Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels — Completed
• Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma — Stopped early
• Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas — Completed
• Study of CPI-200 in Patients With Advanced Tumors — Completed
• Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas — Completed
• Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas — Completed
• Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer — Stopped early